Biocon Ltd Share Price
(BIOCON)
₹331.3▲0.65%
as on 04:01PM, 17 Apr 2025
Biocon Performance
Day's Low
Day's High
₹327.55Day's Price Range₹33352 Week's Low
52 Week's High
₹259.8552-Week Price Range₹404.7
| Returns % | |
| 1 Month Return | -1.23 % |
| 3 Month Return | -16.4 % |
| 1 Year Return | + 23.18 % |
| Market Stats | |
| Previous Close | ₹329.15 |
| Open | ₹329.10 |
| Volume | 9.59L |
| Upper Circuit | ₹362.05 |
| Lower Circuit | ₹296.25 |
| Market Cap | ₹39,517.75Cr |
Biocon Fundamentals
P/E Ratio
48.98
PEG Ratio
-14.75
Market Cap
₹39,517.75 Cr
P/B Ratio
2.91
EPS
10.81
Dividend Yield
0.19
Sector
Pharmaceuticals
ROE
0.97
Mutual Fund Holdings of Biocon
Biocon Analyst Rating
based on 20 analysts
57.89%
Buy
15.79%
Hold
26.32%
Sell
Based on 20 analysts offering long term price targets for Biocon. An average target of ₹380.95
Source: S&P Global Market Intelligence
Biocon Share analysis
Biocon price forecast by 20 analysts
Upside of15.74%
High
₹452
Target
₹380.95
Low
₹260
Biocon target price ₹380.95, a slight upside of 15.74% compared to current price of ₹331.3. According to 20 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Biocon revenue growth forecast
Expected growth rate Q1, FY2027:40.17%
Forecast
Actual
Including amortisation and stock based compensations
Biocon EPS growth forecast
EPS estimate Q1, FY2027:47.89%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Biocon Ltd
Biocon Secures U.S. Launch for Yesafili Biosimilar - 15 Apr, 2025
Biocon Biologics has reached a settlement with Regeneron to commercialize Yesafili, an interchangeable biosimilar to Eylea, in the U.S. by 2026. This agreement enhances Biocon's presence in ophthalmology and includes a similar launch in Canada by July 2025.Biocon Biologics Secures FDA Approval for Jobevne - 10 Apr, 2025
Biocon Biologics has received U.S. FDA approval for Jobevne, a biosimilar to Bevacizumab, enhancing its oncology portfolio. This marks the seventh biosimilar approved in the U.S., reflecting Biocon's commitment to affordable biologics.Biocon Pharma Issues Recall for Cholesterol Medication - 09 Apr, 2025
Biocon Pharma Inc is recalling 2,184 bottles of a cholesterol medication due to failed dissolution specifications, as stated by the USFDA. The Class II recall was initiated on March 17, 2025.Biocon Faces Stock Drop Amid Fundraising and Tariff Concerns - 07 Apr, 2025
Biocon's board approved raising up to ₹600 crore through commercial papers, leading to a 6% drop in shares. Broader market concerns over US tariffs further impacted stock performance.Biocon Board Approves Rs. 600 Crore Paper Issuance - 04 Apr, 2025
Biocon Limited's Board of Directors has approved raising up to Rs. 600 crore through the issuance of commercial papers via private placement, aimed at enhancing liquidity and operational flexibility.Leadership Change and Fundraising Plans at Biocon - 02 Apr, 2025
Peter Bains has stepped down as CEO of Biocon, moving to Syngene International. The board will meet on April 4 to discuss fundraising options following a significant profit decline.Biocon Biologics Secures Major UK Joint Venture Guarantees - 26 Mar, 2025
In October, Biocon Biologics issued guarantees for its UK joint venture, Biocon Biologics UK Ltd, representing one of the largest remittances to the UK in FY25.Biocon Secures FDA Approval for Key Injectable Drug - 24 Mar, 2025
Biocon's subsidiary, Biocon Pharma, has received US FDA approval for Norepinephrine Bitartrate Injection, a critical drug for treating acute hypotension, boosting its complex drug portfolio.
Insights on Biocon Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, -16.0 Cr → 25.1 Cr (in ₹), with an average increase of 163.8% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 7.97% to 8.58% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 3.64K Cr → 3.87K Cr (in ₹), with an average increase of 5.8% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Vimta Labs Ltd has given 166.2% return, outperforming this stock by 170.3%
- NO EFFECT
Against Peers
In the last 1 year, Vimta Labs Ltd has given 115.6% return, outperforming this stock by 92.4%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 60.64% of holdings in Dec 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 18.75% to 18.12% in Dec 2024 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 5.93% to 5.66% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, BIOCON stock has moved down by -1.2%
Biocon Financials
Biocon Index Inclusions
Biocon Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 60.64% | 0.00 | |
| Foreign Institutions | 5.66% | ||
| Mutual Funds | 8.58% | 7.71 | |
| Retail Investors | 18.12% | ||
| Others | 7% | 4.30 |
Biocon Key Indicators
Biocon Valuation
Biocon in the last 5 years
Lowest (24.48x)
March 19, 2024
Today (48.98x)
April 16, 2025
Industry (53.06x)
April 16, 2025
Highest (118.86x)
September 27, 2018
Biocon Earnings and Dividends
Biocon Ltd Earnings Results
Biocon Ltd’s net profit fell -96.2% since last year same period to ₹25.10Cr in the Q3 2024-2025. On a quarterly growth basis, Biocon Ltd has generated 256.88% jump in its net profits since last 3-months.
Read More about Earnings ResultsBiocon Ltd Dividends May,2024
In the quarter ending March 2024, Biocon Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.60%.
Read More about Dividends
Biocon Technicals Summary
Bearish
Neutral
Bullish
Biocon Ltd is currently in a Bearish trading position according to technical analysis indicators.
Biocon Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹39,517.75 Cr | -1.47% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹1,52,750.62 Cr | 29.34% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,09,065.91 Cr | 37.37% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹23,767.76 Cr | -4.14% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| BUY | ₹1,20,851.83 Cr | 30.05% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
About Biocon
Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.
Revenue: ₹3,773.00Cr as on December 2024 (Q4 24)
Net Profit: ₹81.10Cr as on December 2024 (Q4 24)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
| Organisation | Biocon |
| Headquarters | Bangalore |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Biocon Ltd
What is Biocon Ltd price today?
Biocon Ltd share price today stands at ₹331.3, Open: ₹329.1, Previous Close: ₹329.15, High: ₹333, Low: ₹327.55, 52 Week High: ₹404.7, 52 Week Low: ₹259.85.
How to Buy Biocon Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Biocon Ltd shares
What are today's traded volumes of Biocon Ltd?
Today's traded volume of Biocon Ltd(BIOCON) is 9.59L.
What is today's market capitalisation of Biocon Ltd?
Today's market capitalisation of Biocon Ltd(BIOCON) is ₹39517.75Cr.
What is the 52 Week High and Low Range of Biocon Ltd?
How much percentage Biocon Ltd is down from its 52 Week High?
Biocon Ltd (BIOCON) share price is ₹331.3. It is down -18.14% from its 52 Week High price of ₹404.7
How much percentage Biocon Ltd is up from its 52 Week low?
Biocon Ltd (BIOCON) share price is ₹331.3. It is up 27.50% from its 52 Week Low price of ₹259.85